Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Wound healing in cancer patients under immunotherapy

Kuo PJ., Lin PC., Hsieh CH.

Narrative Review on Chronic Wound, published in Int J Surg (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Int J Surg (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40576185
PMCID
PMC12527678
DOI
10.1097/js9.0000000000002819
Citations
1

Abstract (original English)

This comprehensive review examines the impact of cancer immunotherapies on wound healing, focusing on recent clinical evidence. While most cancer patients on immunotherapy heal surgical and accidental wounds without significant impairment, immune system alterations can sometimes delay healing or cause unique wound pathologies. Neoadjuvant immunotherapy before complex surgeries has shown higher wound complication rates in some cohorts, suggesting careful patient selection is needed. Immune checkpoint inhibitors don't typically increase general surgical complication rates, offering reassurance for most procedures. However, immunotherapy can directly cause wounds through immune-related adverse events like bullous pemphigoid or pyoderma gangrenosum, requiring specialized management. For malignant wounds, immunotherapy offers potential benefits by treating the underlying cancer. Management strategies include preoperative planning, careful surgical technique, close postoperative monitoring, and multidisciplinary collaboration. Despite adding complexity to wound healing, immunotherapy's cancer control benefits typically outweigh risks. With appropriate strategies and vigilance for impaired healing or unusual wound presentations, most patients can undergo surgery safely while continuing immunotherapy. Further research is needed to develop evidence-based guidelines for perioperative imm

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansNeoplasmsImmunotherapyWound HealingImmune Checkpoint Inhibitors

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research